Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Fleshner

Showing results (231-240 of 260) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2017
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer ClinicGirish S Kulkarni, Thomas Hermanns, Yanliang Wei, et al.
European Urology Oncology|August 6, 2021
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder CancerTessel E Galesloot, Anne J Grotenhuis, Dimitar Kolev, et al.
Cancer Genetics|June 19, 2026
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancerJasper P Hof, Tessel E Galesloot, Katja K H Aben, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II TrialNeil E Fleshner, Rashid K Sayyid, Aaron R Hansen, et al.
Urologic Oncology|February 22, 2020
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer gradeThomas Hermanns, Andrea J Savio, Ekaterina Olkhov-Mitsel, et al.
JAMA Oncology|September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical TrialSrikala S Sridhar, Normand Blais, Ben Tran, et al.
Endocrine Oncology (Bristol, England)|July 3, 2026
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancerMathew Gorman, Nawaid Usmani, Michael N Pollak, et al.
European Urology|March 9, 2021
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis HypothesisRachel M Glicksman, Ur Metser, Douglass Vines, et al.
European Urology|April 12, 2011
Active surveillance of small renal masses: progression patterns of early stage kidney cancerMichael A S Jewett, Kamal Mattar, Joan Basiuk, et al.
Pageof 26

Showing results (231-240 of 260) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2017
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer ClinicGirish S Kulkarni, Thomas Hermanns, Yanliang Wei, et al.
European Urology Oncology|August 6, 2021
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder CancerTessel E Galesloot, Anne J Grotenhuis, Dimitar Kolev, et al.
Cancer Genetics|June 19, 2026
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancerJasper P Hof, Tessel E Galesloot, Katja K H Aben, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II TrialNeil E Fleshner, Rashid K Sayyid, Aaron R Hansen, et al.
Urologic Oncology|February 22, 2020
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer gradeThomas Hermanns, Andrea J Savio, Ekaterina Olkhov-Mitsel, et al.
JAMA Oncology|September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical TrialSrikala S Sridhar, Normand Blais, Ben Tran, et al.
Endocrine Oncology (Bristol, England)|July 3, 2026
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancerMathew Gorman, Nawaid Usmani, Michael N Pollak, et al.
European Urology|March 9, 2021
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis HypothesisRachel M Glicksman, Ur Metser, Douglass Vines, et al.
European Urology|April 12, 2011
Active surveillance of small renal masses: progression patterns of early stage kidney cancerMichael A S Jewett, Kamal Mattar, Joan Basiuk, et al.
Pageof 26